ClpP Activation: A New Strategy for Drug-Resistant Cancer
Madera Therapeutics pioneered the discovery, optimization, mechanistic understanding, and therapeutic use of highly potent ClpP agonists in cancer. These agents activate ClpP, a mitochondrial protease that creates a distinct therapeutic vulnerability in cancer cells, and have shown activity across cell-based, animal, and patient-derived tumor models, including drug-resistant disease.
ClpP activation is orthogonal to standard cancer therapies, creating a complementary strategy for difficult-to-treat and treatment-resistant cancers. Madera’s broad patent portfolio covers optimized ClpP activators, novel chemical matter, and therapeutic uses across oncology and other disease areas.
Mission Statement
Madera Therapeutics is developing best-in-class ClpP agonist therapeutics that exploit cancer’s mitochondrial vulnerabilities to disrupt tumor survival, overcome treatment resistance, and deliver differentiated therapies for patients with difficult-to-treat cancers.
